Details of the Drug-Related molecule(s) Expression Atlas

General Information of Drug (ID: DML6E6G)

Drug Name
Nomacopan Drug Info
Indication
Disease Entry ICD 11 Status REF
Bullous pemphigoid EB41.0 Phase 3 [1]
Thrombotic microangiopathy 3B65 Phase 3 [2]
Cross-matching ID
TTD Drug ID
DML6E6G

Molecule(s) Related to This Drug


Drug Therapeutic Target (DTT)
DTT Name DTT ID UniProt ID MOA REF
Complement C5 (CO5) TTKANGO CO5_HUMAN Inhibitor [3]

The Expression Level of Molecule(s) between Disease Section and Healthy Individual Tissue

The Studied Disease Bullous pemphigoid
ICD Disease Classification EB41.0
Molecule Name Molecule Type Gene Name p-value Fold-Change Z-score
Complement C5 (CO5) DTT C5 7.69E-01 -0.12 -0.23
Molecular Expression Atlas between Disease Section and Healthy Individual Tissue

References

1 ClinicalTrials.gov (NCT05061771) A Randomized, Part A Partial Blinded and Part B Double Blinded, Placebo-controlled 24-week Clinical Study to Evaluate the Efficacy and Safety of Nomacopan Therapy in Adult Patients With Bullous Pemphigoid Receiving Adjunct Oral Corticosteroid Therapy (ARREST-BP). U.S.National Institutes of Health.
2 ClinicalTrials.gov (NCT04784455) Multicentre Study of Nomacopan (rVA576) in Paediatric Haematopoietic Stem-Cell Transplant Associated Thrombotic Microangiopathy. U.S.National Institutes of Health.
3 Evaluation of Nomacopan for Treatment of Bullous Pemphigoid: A Phase 2a Nonrandomized Controlled Trial. JAMA Dermatol. 2022 Jun 1;158(6):641-649.